NCT07726446招募中2 期
Safety and Effectiveness of Sequential Cryoablation With Rilafup α and Chemotherapy as First-line Treatment for Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: a Multicenter, Prospective, Single-arm, Phase II Clinical Study
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2026年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Objective Response Rate
研究概览
简要总结
This study is a prospective, multicenter, single-arm, open-label Phase II clinical trial, planned to enroll 30 patients with unresectable locally advanced or metastatic iCCA/GBC. Patients will first receive cryoablation treatment, and two weeks after ablation, they will receive 8 cycles of immunotherapy combined with chemotherapy (Relatlimab α plus GC chemotherapy, every 3 weeks). During the maintenance phase, patients will continue with Relatlimab α alone, every 3 weeks, for up to one year. During the combination treatment phase, efficacy will be evaluated every 6 weeks, and during the maintenance phase, every 6 to 9 weeks. From the date of randomization/enrollment, survival follow-ups will be conducted every 3 months (±14 days) for the first 2 years; afterwards, follow-ups will occur every 6 months (±28 days) until the participant dies, is lost to follow-up, or the study ends, whichever comes first.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years, any gender;
- •Histologically confirmed unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma or gallbladder cancer;
- •No prior anti-tumor treatment;
- •At least one measurable target lesion according to RECIST 1.1 tumor evaluation criteria, and at least one lesion suitable for ablation;
- •No active autoimmune disease;
- •No concurrent malignancies;
- •ECOG performance status 0-1;
- •Expected survival ≥ 3 months;
- •Adequate organ and bone marrow function (no transfusion, recombinant human thrombopoietin, or colony-stimulating factor treatment within 2 weeks before first dose), defined as:
- •Blood count: neutrophils (NEUT) ≥ 1.2×10^9/L; platelets (PLT) ≥ 90×10^9/L; hemoglobin ≥ 90 g/dL;
- •Liver function: AST and ALT ≤ 2.5× upper limit of normal (ULN); ALP ≤ 2.5×ULN; total bilirubin (TBIL) ≤ 1.5×ULN; if liver metastases, ALT and AST ≤ 5×ULN;
- •INR ≤ 1.25;
- •Serum creatinine ≤ 1.5× ULN or creatinine clearance (CrCl) ≥ 30 mL/min (using Cockcroft-Gault formula);
- •Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use effective medical contraception from signing the informed consent until 6 months after the last dose;
- •Participants voluntarily join the study, sign the informed consent form, and can comply with scheduled visits and related procedures.
排除标准
- •Previously received systemic anti-tumor treatment;
- •Active brain metastases; patients with asymptomatic brain metastases can be enrolled; for patients clinically suspected of central nervous system metastasis, a CT or MRI must be performed within 28 days before enrollment to rule out central nervous system metastasis;
- •Had other malignant tumors within 5 years before administration (except tumors cured with radical treatment, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical carcinoma in situ, etc.);
- •Allergic to the study drug (Rilafup Alpha Injection, or other immune checkpoint inhibitors);
- •History of unstable angina; newly diagnosed angina within 3 months before screening or myocardial infarction within 6 months before screening; arrhythmias (including QTcF: men ≥ 450 ms, women ≥ 470 ms) requiring long-term use of anti-arrhythmic drugs and NYHA class ≥ II heart failure;
- •Urinalysis showing protein ≥ and confirmed 24-hour urine protein quantification > 1.0g;
- •Infectious pneumonia, non-infectious pneumonia, interstitial pneumonia, or other conditions requiring corticosteroid therapy; history of chronic autoimmune diseases, such as systemic lupus erythematosus; history of ulcerative colitis, Crohn's disease, or other inflammatory bowel diseases; history of chronic diarrhea conditions like irritable bowel syndrome; history of sarcoidosis or tuberculosis; active hepatitis B or C, and HIV infection;
- •Currently participating in interventional clinical research treatment, or have received other study drugs or devices within 4 weeks before first administration;
- •History of substance abuse that cannot be stopped or mental disorders; Any other situation in which the investigator believes the patient is not suitable for participation in this study.
结局指标
主要结局
Objective Response Rate
时间窗: 1 year
ORR
次要结局
- Objective response rate in the subgroup(1 year)
- disease control rate(1 year)
- Progression-free survival(2 years)
- Overall survival(2 years)
- Duration of Response(1 year)
- mRECIST standard evaluation of objective response rate(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Cryoablation Plus Camrelizumab for Advanced Soft Tissue SarcomaNCT07602049Sun Yat-sen University57
尚未招募
不适用
Intralesional Cryosurgery Alone Versus Combined With 5-FU and Triamcinolone for KeloidsKeloidNCT07526168Assiut University32
尚未招募
1 期
The Effect of Cryotherapy on Treatment Outcomes for PulpotomyNCT07303010Sirawut Hiran-us140
招募中
不适用
Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR)Prostate Cancer (Diagnosis)Transperineal CryoablationNCT07567027NYU Langone Health20
招募中
不适用
Luminal Breast Cancer CryoablationBreast CancerNCT07447414Lucía Graña López140